IFNγ-responsiveness of endothelial cells leads to efficient angiostasis in tumours involving down-regulation of Dll4

Journal of Pathology

Volumn 233, Issue 2, 2014, Pages 170-182

  Deng, Jingjing ^a,b   Liu, Xiaoman ^a   Rong, Lijie ^a,b   Ni, Chen ^a,b   Li, Xiao ^a   Yang, Wei ^a,b   Lu, Yu ^a,b   Yan, Xiyun ^a   Qin, Chuan ^c   Zhang, Lianfeng ^c   Qin, Zhihai ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

angiostasis; delta like ligand 4; Dll4; endothelium; IFN ; IFN R; notch pathway

Indexed keywords

DELTA LIKE LIGAND 4; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOTHELIUM CELL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR PROMOTION; TUMOR VASCULARIZATION;

ANGIOSTASIS; DELTA-LIKE LIGAND 4; DLL4; ENDOTHELIUM; IFNΓ; IFNΓR; NOTCH PATHWAY;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERFERON-GAMMA; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, SCID; MICE, TRANSGENIC; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; PROMOTER REGIONS, GENETIC; RECEPTOR, TIE-2; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 84900816359     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4340     Document Type: Article

References (55)

1. Folkman J., Angiogenesis: an organizing principle for drug discovery? Nature Rev Drug Discov 2007; 6: 273-286.
2. Hood JD, Bednarski M, Frausto R, et al., Tumor regression by targeted gene delivery to the neovasculature. Science 2002; 296: 2404-2407.
3. Murphy SP, Tayade C, Ashkar AA, et al., Interferon gamma in successful pregnancies. Biol Reprod 2009; 80: 848-859.
4. Qin Z, Blankenstein T,. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12: 677-686.
5. Qin Z, Schwartzkopff J, Pradera F, et al., A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095-4100.
6. Ko JH, Jung BG, Park YS, et al., Inhibitory effects of interferon-gamma plasmid DNA on DMBA-TPA induced mouse skin carcinogenesis. Cancer Gene Ther 2011; 18: 646-654.
7. Voest EE, Kenyon BM, O'Reilly MS, et al., Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 1995; 87: 581-586.
8. Tannenbaum CS, Wicker N, Armstrong D, et al., Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156: 693-699.
9. Movahedi K, Guilliams M, Van den Bossche J, et al., Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233-4244.
10. Wang Z, Hong J, Sun W, et al., Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006; 116: 2434-2441.
11. Murdoch C, Muthana M, Coffelt SB, et al., The role of myeloid cells in the promotion of tumour angiogenesis. Nature Rev Cancer 2008; 8: 618-631.
12. Facciabene A, Peng X, Hagemann IS, et al., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011; 475: 226-230.
13. Valente G, Ozmen L, Novelli F, et al., Distribution of interferon-gamma receptor in human tissues. Eur J Immunol 1992; 22: 2403-2412.
14. Lu Y, Yang W, Qin C, et al., Responsiveness of stromal fibroblasts to IFN-gamma blocks tumor growth via angiostasis. J Immunol 2009; 183: 6413-6421.
15. Marfaing-Koka A, Devergne O, Gorgone G, et al., Regulation of the production of the RANTES chemokine by endothelial cells. Synergistic induction by IFN-gamma plus TNF-alpha and inhibition by IL-4 and IL-13. J Immunol 1995; 154: 1870-1878.
16. Sgadari C, Farber JM, Angiolillo AL, et al., Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997; 89: 2635-2643.
17. Luster AD, Ravetch JV,. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166: 1084-1097.
18. Saharinen P, Eklund L, Pulkki K, et al., VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med 2011; 17: 347-362.
19. Kuhnert F, Kirshner JR, Thurston G,. Dll4-Notch signaling as a therapeutic target in tumor angiogenesis. Vasc Cell 2011; 3: 20.
20. Patel NS, Li JL, Generali D, et al., Up-regulation of delta-like 4 ligand in human tumor vasculature and the role of basal expression in endothelial cell function. Cancer Res 2005; 65: 8690.
21. Peale FV Jr, Gerritsen ME,. Gene profiling techniques and their application in angiogenesis and vascular development. J Pathol 2001; 195: 7-19.
22. Hayashi H, Kume T,. Foxc transcription factors directly regulate Dll4 and Hey2 expression by interacting with the VEGF-Notch signaling pathways in endothelial cells. PLoS One 2008; 3: e2401.
23. Dufraine J, Funahashi Y, Kitajewski J,. Notch signaling regulates tumor angiogenesis by diverse mechanisms. Oncogene 2008; 27: 5132-5137.
24. Noguera-Troise I, Daly C, Papadopoulos NJ, et al., Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006; 444: 1032-1037.
25. Ridgway J, Zhang G, Wu Y, et al., Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006; 444: 1083-1087.
26. Schlaeger TM, Bartunkova S, Lawitts JA, et al., Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci U S A 1997; 94: 3058-3063.
27. Bach EA, Aguet M, Schreiber RD,. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997; 15: 563-591.
28. Motoike T, Loughna S, Perens E, et al., Universal GFP reporter for the study of vascular development. Genesis 2000; 28: 75-81.
29. Tang Y, Harrington A, Yang X, et al., The contribution of the Tie2+ lineage to primitive and definitive hematopoietic cells. Genesis 2010; 48: 563-567.
30. De Palma M, Venneri MA, Galli R, et al., Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8: 211-226.
31. De Palma M, Murdoch C, Venneri MA, et al., Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol 2007; 28: 519-524.
32. De Palma M, Mazzieri R, Politi LS, et al., Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 2008; 14: 299-311.
33. Schrage A, Loddenkemper C, Erben U, et al., Murine CD146 is widely expressed on endothelial cells and is recognized by the monoclonal antibody ME-9 F1. Histochem Cell Biol 2008; 129: 441-451.
34. Yen W-C, Fischer MM, Hynes M, et al., Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells. Clin Cancer Res 2012; 18: 5374-5386.
35. Lobov IB, Cheung E, Wudali R, et al., The Dll4/Notch pathway controls postangiogenic blood vessel remodeling and regression by modulating vasoconstriction and blood flow. Blood 2011; 117: 6728-6737.
36. Kume T., Foxc2 transcription factor: a newly described regulator of angiogenesis. Trends Cardiovasc Med 2008; 18: 224-228.
37. Souckova K, Kovarik A, Dusek L, et al., Reduced inducibility of SOCS3 by interferon gamma associates with higher resistance of human breast cancer lines as compared to normal mammary epithelial cells. Neoplasma 2009; 56: 379-386.
38. Indraccolo S, Pfeffer U, Minuzzo S, et al., Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol 2007; 178: 1122-1135.
39. Lobov IB, Renard RA, Papadopoulos N, et al., Delta-like ligand 4 (Dll4) is induced by VEGF as a negative regulator of angiogenic sprouting. Proc Natl Acad Sci U S A 2007; 104: 3219-3224.
40. Rogosin S, Sandler AB,. Beyond bevacizumab: antiangiogenic agents. Clin Lung Cancer 2012; 13: 326-333.
41. Patel NS, Dobbie MS, Rochester M, et al., Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer. Clin Cancer Res 2006; 12: 4836-4844.
42. Banerjee S, Kaye SB,. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res 2013; 19: 961-968.
43. Harrington LS, Sainson RC, Williams CK, et al., Regulation of multiple angiogenic pathways by Dll4 and Notch in human umbilical vein endothelial cells. Microvasc Res 2008; 75: 144-154.
44. Williams CK, Li JL, Murga M, et al., Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood 2006; 107: 931-939.
45. Guenzi E, Topolt K, Lubeseder-Martellato C, et al., The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO J 2003; 22: 3772-3782.
46. Romagnani P, Lasagni L, Annunziato F, et al., CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol 2004; 25: 201-209.
47. Andonegui G, Zhou H, Bullard D, et al., Mice that exclusively express TLR4 on endothelial cells can efficiently clear a lethal systemic Gram-negative bacterial infection. J Clin Invest 2009; 119: 1921-1930.
48. Gleave ME, Elhilali M, Fradet Y, et al., Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998; 338: 1265-1271.
49. Dunn GP, Koebel CM, Schreiber RD,. Interferons, immunity and cancer immunoediting. Nature Rev Immunol 2006; 6: 836-848.
50. Wiesenfeld M, O'Connell MJ, Wieand HS, et al., Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J Clin Oncol 1995; 13: 2324-2329.
51. Jett JR, Maksymiuk AW, Su JQ, et al., Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. J Clin Oncol 1994; 12: 2321-2326.
52. Liu S, Rong L, Deng J, et al., TNFR2 expression on non-bone marrow-derived cells is crucial for lipopolysaccharide-induced septic shock and downregulation of soluble TNFR2 level in serum. Cell Mol Immunol 2011; 8: 164-171.
53. Tager AM, Kradin RL, LaCamera P, et al., Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10. Am J Respir Cell Mol Biol 2004; 31: 395-404.
54. Zhao X, Rong L, Li X, et al., TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest 2012; 122: 4094-4104.
55. Lu Y, Xiong Y, Huo Y, et al., Grb-2-associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A-endothelial NOS pathway. Proc Natl Acad Sci U S A 2011; 108: 2957-2962.